| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.41 MB | Adobe PDF |
Orientador(es)
Resumo(s)
We conducted a multicentre hospital-based test-negative case–control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36); 20% (95% CI: −4–39) against A(H3N2) and 56% (95% CI: 22–75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.
Descrição
Palavras-chave
SARI Patients Hospital Influenza Test-negative Design Vaccine Effectiveness Cuidados de Saúde Vacina Gripe Efetividade VEBIS-LOT1 Europe
Contexto Educativo
Citação
Influenza Other Respir Viruses. 2024 Feb;18(2):e13255. doi: 10.1111/irv.13255
Editora
Wiley